Skip to main content
A randomized multicenter trial conducted almost a decade ago and reported in 2004 showed docetaxel plus prednisone to be superior to mitoxantrone plus prednisone for patients with hormone refractory prostate cancer.

Docetaxel for Advanced Prostate Cancer

A randomized multicenter trial conducted almost a decade ago and reported in 2004 showed docetaxel plus prednisone to be superior to mitoxantrone plus prednisone for patients with hormone refractory prostate cancer.